Treating posttraumatic stress disorder and alcohol use disorder comorbidity: Current pharmacological therapies and the future of MDMA-integrated psychotherapy
Restricted accessReview articleFirst published online December, 2023
Treating posttraumatic stress disorder and alcohol use disorder comorbidity: Current pharmacological therapies and the future of MDMA-integrated psychotherapy
Posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) frequently co-occur in patients who have experienced trauma. This comorbidity leads to a vicious cycle where PTSD symptoms beget heavy drinking and vice versa. There are no FDA-approved medications to treat PTSD-AUD; therefore, individuals suffering from this comorbidity are treated with medication approved to treat the disorders separately or with off-label pharmacological interventions. However, these medications are limited in their efficacy for treating PTSD-AUD comorbidity. Emerging research on the nonclassical psychedelic drug 3,4-methylenedioxymethamphetamine (MDMA) suggests that it may be an effective drug used in conjunction with psychotherapy. The following reviews the current research for clinical pharmacotherapies, as well as MDMA-integrative psychotherapy as they pertain to PTSD and AUD in isolation and co-occurrence. Future directions for the role of psychedelic-integrative therapy for the treatment of this comorbidity are discussed.
American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association.
2.
BackSEKilleenTBadourCL, et al (2019). Concurrent treatment of substance use disorders and PTSD using prolonged exposure: A randomized clinical trial in military veterans. Addict Behav90: 369–377.
3.
BahjiABachPDanilewitzM, et al (2022) Pharmacotherapies for adults with alcohol use disorders: A systematic review and network meta-analysis. J Addict Med16: 630–638.
4.
BalldinJBerglundMBorgS, et al (2003). A 6-month controlled naltrexone study: Combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res27: 1142–1149.
5.
BatkiSLPenningtonDLLasherB, et al (2014) Topiramate treatment of alcohol use disorder in veterans with posttraumatic stress disorder: A randomized controlled pilot trial. Alcohol Clin Exp Res38: 2169–2177.
6.
BlakeDDWeathersFWNagyLM, et al (1995) The development of a clinician-administered PTSD scale. J Trauma Stress8: 75–90.
7.
BookSWThomasSERandallPK, et al (2008) Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder. J Anxiety Disord22: 310–318.
8.
BorrelliJJrStarrADownsDL, et al (2019) Prospective study of the effectiveness of paroxetine on the onset of posttraumatic stress disorder, depression, and health and functional outcomes after trauma. J Orthop Trauma33: e58–e63.
9.
BradyKPearlsteinTAsnisGM, et al (2000) Efficacy and safety of sertraline treatment of posttraumatic stress disorder: A randomized controlled trial. JAMA283: 1837–1844.
10.
BradyKTSonneSAntonRF, et al (2005) Sertraline in the treatment of co-occurring alcohol dependence and posttraumatic stress disorder. Alcohol Clin Exp Res29: 395–401.
11.
DanforthALGrobCSStrubleC, et al (2018) Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacology (Berl)235: 3137–3148.
12.
DavidsonJRLandermanLRFarfelGM, et al (2002). Characterizing the effects of sertraline in post-traumatic stress disorder. Psychol Med32: 661–670.
13.
DavidsonJRothbaumBOTuckerP, et al (2006) Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. J Clin Psychopharmacol26: 259–267.
14.
DebellFFearNTHeadM, et al (2014) A systematic review of the comorbidity between PTSD and alcohol misuse. Soc Psychiatry Psychiatr Epidemiol49: 1401–1425.
15.
de la TorreRFarreM (2004) Neurotoxicity of MDMA (ecstasy): The limitations of scaling from animals to humans. Trends Pharmacol Sci25: 505–508.
16.
DworkinERWanklynSStasiewiczPR, et al (2018). PTSD symptom presentation among people with alcohol and drug use disorders: Comparisons by substance of abuse. Addict Behav76: 188–194.
17.
EvrenCSarVDalbudakE, et al (2011). Lifetime PTSD and quality of life among alcohol-dependent men: Impact of childhood emotional abuse and dissociation. Psychiatry Res186: 85–90.
18.
FeducciaAAJeromeLYazar-KlosinskiB, et al (2019) Breakthrough for trauma treatment: Safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline. Front Psychiatry10: 650.
19.
FetznerMGMcmillanKASareenJ, et al (2011) What is the association between traumatic life events and alcohol abuse/dependence in people with and without PTSD? Findings from a nationally representative sample. Depress Anxiety28: 632–638.
20.
FoaEBYuskoDAMcleanCP, et al (2013) Concurrent naltrexone and prolonged exposure therapy for patients with comorbid alcohol dependence and PTSD: A randomized clinical trial. JAMA310: 488–495.
21.
FrommbergerUStieglitzRDNybergE, et al (2004) Comparison between paroxetine and behaviour therapy in patients with posttraumatic stress disorder (PTSD): A pilot study. Int J Psychiatry Clin Pract8: 19–23.
22.
FullerRKGordisE (2004) Does disulfiram have a role in alcoholism treatment today?Addiction99: 21–24.
23.
GarbuttJCKranzlerHRO’MalleySS, et al (2005) Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: A randomized controlled trial. JAMA293: 1617–1625.
24.
Garcia-RomeuADavisAKErowidE, et al (2019) Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: An online survey. Front Psychiatry10: 955.
25.
Garcia-RomeuAKersgaardBAddyPH (2016) Clinical applications of hallucinogens: A review. Exp Clin Psychopharmacol24: 229–268.
26.
GilpinNWWeinerJL (2017) Neurobiology of comorbid post-traumatic stress disorder and alcohol-use disorder. Genes Brain Behav16: 15–43.
27.
GoldsteinSCSchickMRWeyandtLL, et al (2023) Posttraumatic stress as a moderator of the association between HPA-axis functioning and alcohol use disorder among a community sample of women currently experiencing intimate partner violence. Exp Clin Psychopharmacol31: 163–173.
28.
GrantBF (1994) Alcohol consumption, alcohol abuse and alcohol dependence. The United States as an example. Addiction89: 1357–1365.
29.
GrantBFGoldsteinRBSahaTD, et al (2015) Epidemiology of DSM-5 alcohol use disorder: results from the national epidemiologic survey on alcohol and related conditions III. JAMA Psychiatry72: 757–766.
30.
GreenB (2014) Prazosin in the treatment of PTSD. J Psychiatr Pract20: 253–259.
31.
Haass-KofflerCL (2023) Utilizing precision medicine to treat alcohol use disorder: A commentary on the alpha1 receptor antagonist. Alcohol Clin Exp Res47: 432–434.
32.
Haass-KofflerCLGoodyearKZywiakWH, et al (2017). Higher pretreatment blood pressure is associated with greater alcohol drinking reduction in alcohol-dependent individuals treated with doxazosin. Drug Alcohol Depend177: 23–28.
33.
Haass-KofflerCLKennaGA (2013) Bacchus by caravaggio as the visual diagnosis of alcohol use disorder from the fifth edition of the diagnostic and statistical manual of mental disorders (DSM-5). Front Psychiatry4: 86.
34.
Haass-KofflerCLSwiftRMLeggioL (2018) Noradrenergic targets for the treatment of alcohol use disorder. Psychopharmacology (Berl)235: 1625–1634.
35.
HakeHSDavisJKPWoodRR, et al (2019) 3,4-methylenedioxymethamphetamine (MDMA) impairs the extinction and reconsolidation of fear memory in rats. Physiol Behav199: 343–350.
36.
HelzerJERobinsLNMcevoyL (1987) Post-traumatic stress disorder in the general population. Findings of the epidemiologic catchment area survey. N Engl J Med317: 1630–1634.
37.
HienDALevinFRRuglassLM, et al (2015). Combining seeking safety with sertraline for PTSD and alcohol use disorders: A randomized controlled trial. J Consult Clin Psychol83: 359–369.
38.
HienDAMorgan-LopezAASaavedraLM, et al (2023) Project harmony: A meta-analysis with individual patient data on behavioral and pharmacologic trials for comorbid posttraumatic stress and alcohol or other drug use disorders. Am J Psychiatry180: 155–166.
39.
JorgensenCHPedersenBTonnesenH (2011) The efficacy of disulfiram for the treatment of alcohol use disorder. Alcohol Clin Exp Res35: 1749–1758.
40.
Kehle-ForbesSMChenSPolusnyMA, et al (2019) A randomized controlled trial evaluating integrated versus phased application of evidence-based psychotherapies for military veterans with comorbid PTSD and substance use disorders. Drug Alcohol Depend205: 107647.
41.
KolbrichEAGoodwinRSGorelickDA, et al (2008) Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. Ther Drug Monit30: 320–332.
42.
KranzlerHRSoykaM (2018) Diagnosis and pharmacotherapy of alcohol use disorder: A review. JAMA320: 815–824.
43.
KrystalJHDavisLLNeylanTC, et al (2017) It is time to address the crisis in the pharmacotherapy of posttraumatic stress disorder: A consensus statement of the PTSD psychopharmacology working group. Biol Psychiatry82: e51–e59.
44.
LancasterCLGrosDFMullarkeyMC, et al (2020) Does trauma-focused exposure therapy exacerbate symptoms among patients with comorbid PTSD and substance use disorders?Behav Cogn Psychother48: 38–53.
45.
LatimerDStockerMDSayersK, et al (2021) MDMA to treat PTSD in adults. Psychopharmacol Bull51: 125–149.
46.
LiangJOlsenRW (2014) Alcohol use disorders and current pharmacological therapies: The role of GABA(A) receptors. Acta Pharmacol Sin35: 981–993.
47.
LittenRZWilfordBBFalkDE, et al (2016) Potential medications for the treatment of alcohol use disorder: An evaluation of clinical efficacy and safety. Subst Abus37: 286–298.
48.
LuomaJBChwylCBathjeGJ, et al (2020) A meta-analysis of placebo-controlled trials of psychedelic-assisted therapy. J Psychoactive Drugs52: 289–299.
49.
MannKLehertPMorganMY (2004) The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: Results of a meta-analysis. Alcohol Clin Exp Res28: 51–63.
50.
Maria-RiosCEMorrowJD (2020) Mechanisms of shared vulnerability to post-traumatic stress disorder and substance use disorders. Front Behav Neurosci14: 6.
51.
MasonBJCreanR (2007) Acamprosate in the treatment of alcohol dependence: clinical and economic considerations. Expert Rev Neurother7: 1465–1477.
52.
MavranezouliIMegnin-ViggarsODalyC, et al (2020) Psychological treatments for post-traumatic stress disorder in adults: A network meta-analysis. Psychol Med50: 542–555.
53.
MitchellJMBogenschutzMLiliensteinA, et al (2021) MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nat Med27: 1025–1033.
54.
MutschlerJGrosshansMSoykaM, et al (2016) Current findings and mechanisms of action of disulfiram in the treatment of alcohol dependence. Pharmacopsychiatry49: 137–141.
55.
NajavitsLMClarkHWDiclementeCC, et al (2020) PTSD / substance use disorder comorbidity: Treatment options and public health needs. Curr Treat Options Psychiatry7: 544–558.
56.
NaPJRalevskiEJegedeO, et al (2021) Depression and/or PTSD comorbidity affects response to antidepressants in those with alcohol use disorder. Front Psychiatry12: 768318.
57.
NardouRLewisEMRothhaasR, et al (2019) Oxytocin-dependent reopening of a social reward learning critical period with MDMA. Nature569: 116–120.
58.
NicholsDE (2022) Entactogens: How the name for a novel class of psychoactive agents originated. Front Psychiatry13: 863088.
59.
NormanSBTrimRHallerM, et al (2019) Efficacy of integrated exposure therapy vs integrated coping skills therapy for comorbid posttraumatic stress disorder and alcohol use disorder: A randomized clinical trial. JAMA Psychiatry76: 791–799.
60.
OehenP., et al. (2013). “A randomized, controlled pilot study of MDMA (± 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD).”J Psychopharmacol27(1): 40–52.
61.
Ot’AloraGMGrigsbyJPoulterB, et al (2018) 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial. J Psychopharmacol32: 1295–1307.
62.
PetrakisILDesaiNGueorguievaR, et al (2016) Prazosin for veterans with posttraumatic stress disorder and comorbid alcohol dependence: A clinical trial. Alcohol Clin Exp Res40: 178–186.
63.
PetrakisILPolingJLevinsonC, et al (2006) Naltrexone and disulfiram in patients with alcohol dependence and comorbid post-traumatic stress disorder. Biol Psychiatry60: 777–783.
64.
PetrakisILRalevskiEDesaiN, et al (2012) Noradrenergic vs serotonergic antidepressant with or without naltrexone for veterans with PTSD and comorbid alcohol dependence. Neuropsychopharmacology37: 996–1004.
65.
PopielAZawadzkiBPraglowskaE, et al (2015) Prolonged exposure, paroxetine and the combination in the treatment of PTSD following a motor vehicle accident. A randomized clinical trial–The “TRAKT” study. J Behav Ther Exp Psychiatry48: 17–26.
66.
RalevskiEOlivera-FigueroaLAPetrakisI (2014) PTSD and comorbid AUD: A review of pharmacological and alternative treatment options. Subst Abuse Rehabil5: 25–36.
67.
RaskindMAMillardSPPetrieEC, et al (2016) Higher pretreatment blood pressure is associated with greater posttraumatic stress disorder symptom reduction in soldiers treated with prazosin. Biol Psychiatry80: 736–742.
68.
RaskindMAPetersonKWilliamsT, et al (2013) A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan. Am J Psychiatry170: 1003–1010.
69.
RaskindMAThompsonCPetrieEC, et al (2002) Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder. J Clin Psychiatry63: 565–568.
70.
RehmJShieldKD (2019) Global burden of alcohol use disorders and alcohol liver disease. Biomedicines7: 99.
71.
RojasSMBujarskiSBabsonKA, et al (2014) Understanding PTSD comorbidity and suicidal behavior: associations among histories of alcohol dependence, major depressive disorder, and suicidal ideation and attempts. J Anxiety Disord28: 318–325.
72.
SamuelsonKWNeylanTCMetzlerTJ, et al (2006) Neuropsychological functioning in posttraumatic stress disorder and alcohol abuse. Neuropsychology20: 716–726.
73.
SchaferILotzinAHillerP, et al (2019) A multisite randomized controlled trial of seeking safety vs. relapse prevention training for women with co-occurring posttraumatic stress disorder and substance use disorders. Eur J Psychotraumatol10: 1577092.
74.
SchimmentiABillieuxJSantoroG, et al (2022) A trauma model of substance use: Elaboration and preliminary validation. Addict Behav134: 107431.
75.
SchraderCRossA (2021) A review of PTSD and current treatment strategies. Mo Med118: 546–551.
76.
SessaBHigbedLO’BrienS, et al (2021) First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder. J Psychopharmacol35: 375–383.
77.
SimpsonTLMalteCADietelB, et al (2015) A pilot trial of prazosin, an alpha-1 adrenergic antagonist, for comorbid alcohol dependence and posttraumatic stress disorder. Alcohol Clin Exp Res39: 808–817.
78.
SolomonSDavidsonJ(1997) Trauma: Prevalence, impairment, service use, and cost. J Clin Psychiatry58: 5–11.
79.
StrausEHallerMLyonsRC, et al (2018) Functional and psychiatric correlates of comorbid post-traumatic stress disorder and alcohol use disorder. Alcohol Res39: 121–129.
80.
Subbie-Saenz de ViteriSPandeyAPandeyG, et al (2020) Pathways to post-traumatic stress disorder and alcohol dependence: Trauma, executive functioning, and family history of alcoholism in adolescents and young adults. Brain Behav10: e01789.
81.
SuhJJPettinatiHMKampmanKM, et al (2006) The status of disulfiram: A half of a century later. J Clin Psychopharmacol26: 290–302.
82.
TaylorMPetrakisIRalevskiE (2017) Treatment of alcohol use disorder and co-occurring PTSD. Am J Drug Alcohol Abuse43: 391–401.
83.
TuckerPTrautmanRPWyattDB, et al (2007) Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry68: 201–206.
84.
WallachJDRheeTGEdelmanEJ, et al (2022). U.S. prescribing of on-and-off-label medications for alcohol use disorder in outpatient visits: NAMCS 2014 to 2016. J Gen Intern Med37: 495–498.
85.
WitkiewitzKLittenRZLeggioL (2019) Advances in the science and treatment of alcohol use disorder. Sci Adv5: eaax4043.
86.
YehMSMariJJCostaMC, et al (2011) A double-blind randomized controlled trial to study the efficacy of topiramate in a civilian sample of PTSD. CNS Neurosci Ther17: 305–310.
87.
ZhangAPriceJLLeonardD, et al (2020) Alcohol use disorder masks the effects of childhood adversity, lifetime trauma, and chronic stress on hypothalamic-pituitary-adrenal axis reactivity. Alcohol Clin Exp Res44: 1192–1203.
88.
ZoellnerLARoy-ByrnePPMavissakalianM, et al (2019) Doubly randomized preference trial of prolonged exposure versus sertraline for treatment of PTSD. Am J Psychiatry176: 287–296.
89.
ZoharJAmitalDCroppHD, et al (2022) Update on the epidemiology, diagnosis, and treatment of posttraumatic stress disorder. Dialogues Clin Neurosci2: 37–43.
